Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 8/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
| ▸ | DNA2 | P51530 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064138 | 0.90 | CDC7 (0.50) | FBP1CDC7 | |
| SCHEMBL16336576 | 0.87 | BTK (0.48) | DHODHKDM4AKDM5AKDM4CKDM5B | |
| SCHEMBL16382680 | 0.79 | TSHR (0.45) | FBP1TDP1DTYMKDNA2CASP6 | |
| SCHEMBL19009089 | 0.79 | DTYMK (0.44) | FBP1TDP1DTYMKDNA2CASP6 | |
| SCHEMBL5193454 | 0.73 | CRHBP (0.59) | CRHBPCRHR2MAPTTDP1DTYMK | |
| SCHEMBL3009122 | 0.73 | APEX1 (0.50) | DHODHFBP1CRHBPCRHR2CASP6 | |
| SCHEMBL2778988 | 0.73 | CTSB (0.59) | KDM4EMAPTTDP1DTYMKDNA2 | |
| SCHEMBL29475630 | 0.73 | CTSB (0.59) | KDM4EMAPTTDP1DTYMKDNA2 | |
| SCHEMBL25326973 | 0.73 | LMNA (0.53) | FBP1CRHBPCRHR2KDM4EMAPT | |
| SCHEMBL8809899 | 0.71 | DHODH (0.62) | DHODHKDM4AKDM5AKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| CN-101687036-A | CHK1 inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies | ASTRAZENECA AB | 2010-03-31 | — | — | CN | disclosed |
| EP-2144630-A2 | CHK1 INHIBITORS WITH B CELL DEPLETING ANTIBODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | AstraZeneca AB (SE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| WO-2008132500-A2 | CHKL INHIBITORS WITH B CELL DEPLETING ANTIBODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
| CN-101189243-A | Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors | ASTRAZENECA AB (SE) | 2008-05-28 | — | — | CN | disclosed |
| EP-1869052-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106326-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | DHODH 1642/4885KDM4A 2374/4885KDM5A 2817/4885 |
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | CHEK1, CHEK2, MCL1 | DHODH 1830/4885KDM4A 399/4885KDM5A 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.